Where Wellness & Culture Connect
Where Wellness & Culture Connect
Lilly unites caring with discovery to create medicines that make life better for people around the world. Over 47 million people count on Lilly medicines each year. In the nearly 150 years we’ve been in business, we’ve developed and delivered trusted medicines that help people get better, feel better and live better.
Inclusive representation in clinical trials is critical – it helps our researchers ensure that we’re making medicines that will be as effective as possible for patients who use them.
Lilly’s partnership with BlackDoctor.org aims to educate and encourage clinical trial participation and awareness.
LEARN MORE ABOUT LILLY TRIALS
-
TOPAZ-UC: A Phase 2, Multicenter, Randomized, Double-Blind, Active- Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight (COMMIT-CD)
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
-
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
-
Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis (Adorable-1)
Footer
Ask me something!
